{
  "as_of": "2026-11-14",
  "slug": "botulinum-toxin",
  "title": "肉毒桿菌素新藥全景",
  "title_en": "Botulinum Toxin Drug Landscape",
  "scope": "以 A 型肉毒桿菌素皺眉紋藥物為範圍；各產品效價單位不互換，未做頭對頭時不排持效長短。",
  "scope_en": "Type A botulinum toxins for glabellar lines. Potency units are product-specific and are not interchangeable; duration is not ranked across separate trials.",
  "short_answers": [
    "截至 2026-11-14，AbbVie、Ipsen、Merz、韓國 Hugel 及 Daewoong 製造的產品已有美國皺眉紋核准；鼎晉 OBI-858 仍在台灣三期。",
    "鼎晉於 2026-09-07 公告 OBI-858 一年重複劑量二期完成，超過半數受試者一年僅接受 1 或 2 次治療；該結果不能取代三期主要終點。",
    "鼎晉於 2026-09-07 仍預計 2026 年完成 OBI-858 三期並申請查驗登記；兩項試驗主要終點結果將決定台灣候選能否追近已核准產品。"
  ],
  "short_answers_en": [
    "As of 2026-11-14, products from AbbVie, Ipsen, Merz, Korea’s Hugel and Daewoong had US glabellar-line approvals; Taiwan’s OBI-858 remained in Phase 3.",
    "OBIGEN reported on 2026-09-07 that over half of participants received only 1 or 2 treatments during its one-year repeat-dose Phase 2; this does not replace Phase 3 primary endpoints.",
    "OBIGEN still targeted Phase 3 completion in 2026 in its 2026-09-07 announcement, followed by a registration application; pivotal endpoint results will determine its progress toward approved products."
  ],
  "asia_section": "台灣鼎晉的兩項樞紐三期於 2026-03-16 公告完成約 600 人收案，涵蓋 16 個中心；美國二期 IND 受理與上市許可分開。韓國 Hugel 的 Letybo 與 Daewoong 製造、Evolus 商業化的 Jeuveau 已有美國核准。",
  "asia_section_en": "Taiwan’s OBIGEN announced enrollment of approximately 600 participants across 16 centers in its two pivotal trials on 2026-03-16; a US Phase 2 IND is distinct from marketing approval. Korea’s Hugel Letybo and Daewoong-manufactured, Evolus-marketed Jeuveau have US approvals.",
  "selection_inputs": [
    "IPO:7876",
    "IPO:7686"
  ],
  "assets": [
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab"
      ],
      "source_ids": [
        "bot-abbvie"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Botox Cosmetic／onabotulinumtoxinA",
      "asset_en": "Botox Cosmetic / onabotulinumtoxinA",
      "company": "AbbVie",
      "company_en": "AbbVie",
      "country": "美國",
      "country_en": "US",
      "mechanism": "A 型肉毒神經毒素",
      "mechanism_en": "Botulinum neurotoxin type A",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "皺眉紋等，依標籤",
      "indication_en": "Glabellar lines and label-specific indications",
      "latest": "既有核准產品；效價單位不與其他產品換算",
      "latest_en": "Established approved product; units are not interchangeable"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71313a04-1349-4c26-b840-a39e4a3ddaed"
      ],
      "source_ids": [
        "bot-ipsen"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Dysport／abobotulinumtoxinA",
      "asset_en": "Dysport / abobotulinumtoxinA",
      "company": "Ipsen",
      "company_en": "Ipsen",
      "country": "法國",
      "country_en": "France",
      "mechanism": "A 型肉毒神經毒素",
      "mechanism_en": "Botulinum neurotoxin type A",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "皺眉紋等，依標籤",
      "indication_en": "Glabellar lines and label-specific indications",
      "latest": "Ipsen 產品；醫美商業權與製造方分開",
      "latest_en": "Ipsen product; aesthetic commercialization rights are distinct"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccdc3aae-6e2d-4cd0-a51c-8375bfee9458"
      ],
      "source_ids": [
        "bot-merz"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Xeomin／incobotulinumtoxinA",
      "asset_en": "Xeomin / incobotulinumtoxinA",
      "company": "Merz",
      "company_en": "Merz",
      "country": "德國",
      "country_en": "Germany",
      "mechanism": "A 型肉毒神經毒素",
      "mechanism_en": "Botulinum neurotoxin type A",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "上臉部皺紋，依標籤",
      "indication_en": "Upper facial lines, per label",
      "latest": "標籤有皺眉紋資料；不以分子大小推算臨床持效",
      "latest_en": "Glabellar-line evidence on label; molecular size does not prove duration"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "2024-02-29",
      "sources": [
        "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-letybo"
      ],
      "source_ids": [
        "bot-hugel"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Letybo／letibotulinumtoxinA",
      "asset_en": "Letybo / letibotulinumtoxinA",
      "company": "Hugel",
      "company_en": "Hugel",
      "country": "韓國",
      "country_en": "South Korea",
      "mechanism": "A 型肉毒神經毒素",
      "mechanism_en": "Botulinum neurotoxin type A",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "成人中重度皺眉紋",
      "indication_en": "Adult moderate-to-severe glabellar lines",
      "latest": "FDA 2024-02-29 核准；三試驗共 1,271 人",
      "latest_en": "FDA approval 2024-02-29; 1,271 participants across three trials"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "2019",
      "sources": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761085Orig1s000MultiR.pdf"
      ],
      "source_ids": [
        "bot-daewoong"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Jeuveau／prabotulinumtoxinA",
      "asset_en": "Jeuveau / prabotulinumtoxinA",
      "company": "Daewoong（製造）／Evolus（美國商業化）",
      "company_en": "Daewoong (manufacturer) / Evolus (US commercialization)",
      "country": "韓國／美國",
      "country_en": "South Korea / US",
      "mechanism": "A 型肉毒神經毒素",
      "mechanism_en": "Botulinum neurotoxin type A",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "成人中重度皺眉紋",
      "indication_en": "Adult moderate-to-severe glabellar lines",
      "latest": "FDA 審查文件確認韓國 Daewoong 製造",
      "latest_en": "FDA review identifies Daewoong as manufacturer"
    },
    {
      "section": "clinical",
      "trials": [
        "OBI-858-004",
        "OBI-858-005"
      ],
      "date": "2026-09-07",
      "sources": [
        "https://www.obigenpharma.com/en/announcements/announcements-19",
        "https://www.obigenpharma.com/en/announcements/0907-announcement-123-obi858"
      ],
      "source_ids": [
        "bot-obi",
        "bot-obi-new"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "OBI-858",
      "asset_en": "OBI-858",
      "company": "鼎晉生技",
      "company_en": "OBIGEN Pharma",
      "country": "台灣",
      "country_en": "Taiwan",
      "mechanism": "760 kDa A 型肉毒複合體",
      "mechanism_en": "760 kDa type A toxin complex",
      "route": "肌肉注射",
      "route_en": "Intramuscular",
      "stage": "台灣三期",
      "stage_en": "Taiwan Phase 3",
      "indication": "中重度皺眉紋",
      "indication_en": "Moderate-to-severe glabellar lines",
      "latest": "兩項三期約 600 人、16 中心；第 4 週 GLS 改善至少 2 級為主要終點；重複劑量二期完成",
      "latest_en": "Two Phase 3 trials: about 600 participants, 16 centers; primary endpoint: GLS improvement ≥2 grades at Week 4; repeat-dose Phase 2 completed"
    }
  ],
  "number_checks": [
    [
      "B1",
      "OBI-858 複合體分子量",
      "760 kDa",
      "bot-obi",
      "760 kDa"
    ],
    [
      "B2",
      "兩項三期合計收案（約數）",
      "約 600 人",
      "bot-obi",
      "600"
    ],
    [
      "B3",
      "兩項三期合計中心數",
      "16 個",
      "bot-obi",
      "16"
    ],
    [
      "B4",
      "Letybo 三試驗總患者數",
      "1,271 人",
      "bot-hugel",
      "1,271"
    ],
    [
      "B5",
      "OBI-858 第四週主要終點評估時間",
      "4 週",
      "bot-obi",
      "Week 4"
    ]
  ],
  "not_listed_unconfirmed": [],
  "not_listed_note": "",
  "not_listed_note_en": "",
  "summary_expected": {
    "total": 6,
    "approved": 5,
    "clinical": 1,
    "phase2_3": 0,
    "discontinued": 0,
    "asia": 3,
    "taiwan": 1
  }
}
